IMCR
Immunocore Holdings Plc
NASDAQ · Healthcare · Biotechnology · GB
$31.27
−4.11%Oct 29, 2026, 13:00 UTC
Immunocore Holdings plc announced that it will present Phase 1 data on brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at a late-breaking oral session during the 2026 SITC meeting.
Source:Oct 15, 2026, 11:00 UTC
Immunocore announced that the first patient with type 1 diabetes had been dosed in the Phase 1 trial of IMC-S118AI.
Source:Sep 14, 2026, 11:00 UTC
Immunocore Holdings plc announced that target enrollment of 540 patients has been achieved in the registrational Phase 3 TEBE-AM trial evaluating KIMMTRAK (tebentafusp) as monotherapy and with pembrolizumab in previously treated advanced melanoma.
Source:Aug 6, 2026, 00:00 UTC
Immunocore Holdings plc reported Q2 2026 net revenue of $115.9 million, up 18% year-over-year, with a net loss of $0.8 million and diluted EPS of -$0.02.